Table 1 Demographics and clinical features of patients with ILD and a positive anti-Ro52 antibody. Clinical features were compared between patients with anti-Ro52 alone vs anti-Ro52 plus an additional myositis-specific autoantibody (including anti-Jo-1, anti-PL-12, anti-PL-7, anti-EJ, anti-OJ, anti-Mi-2, anti-SRP, anti-MDA5, anti-NXP2, or anti-TIF-1γ)
From: Presentations and outcomes of interstitial lung disease and the anti-Ro52 autoantibody
Variable | All patients n = 73 | Stratified by Autoantibodies | |||
|---|---|---|---|---|---|
Isolated Anti-Ro52 n = 50 | Anti-Ro52 plus myositis-specific autoAb n = 23 | Raw p-value | Adjusted p-value* | ||
Age, years median [range] | 68 [23–90] | 68.5 [23–90] | 68 [37–83] | 0.75 | 1.0 |
Male, n (%) | 45 (61.6%) | 31 (62%) | 14 (60.9%) | 0.93 | 1.0 |
Ethnicity, n (%) | 0.53 | 1.0 | |||
African American | 7 (9.6%) | 5 (10%) | 2 (8.7%) | ||
Asian | 6 (8.2%) | 3 (6.0%) | 3 (13%) | ||
Hispanic | 4 (5.5%) | 2 (4.0%) | 2 (8.7%) | ||
White | 56 (76.7%) | 40 (80%) | 16 (69.6%) | ||
Smoking history, n (%) | 0.43 | 1.0 | |||
Current/Former | 43 (58.9%) | 31 (62%) | 12 (52.2%) | ||
Never | 30 (41.1%) | 19 (38%) | 11 (47.8%) | ||
Duration of pulmonary symptoms, n (%) | 0.59 | 1.0 | |||
Acute (<1 week) | 9 (12.3%) | 7 (14%) | 2 (8.7%) | ||
Subacute (1 week-6 mo) | 14 (19.2%) | 8 (16%) | 6 (26.1%) | ||
Chronic (>6 months) | 48 (65.8%) | 34 (68%) | 14 (60.9%) | ||
None | 2 (2.7%) | 1 (2%) | 1 (4.4%) | ||
ICU admission on presentation, n (%) | 13 (17.8%) | 10 (20%) | 3 (13%) | 0.74 | 1.0 |
Rheumatologic symptoms, n (%) | |||||
Myalgias | 23 (31.5%) | 15 (30%) | 8 (34.8%) | 0.68 | 1.0 |
Mechanic’s hands | 10 (13.7%) | 3 (6%) | 7 (30.4%) | 0.01 | 0.24 |
Gottron’s papules | 2 (2.7%) | 1 (2%) | 1 (4.4%) | 0.53 | 1.0 |
Heliotrope rash | 2 (2.7%) | 2 (4%) | 0 (0%) | 1.0 | 1.0 |
Other rash | 13 (17.8%) | 7 (14%) | 6 (26.1%) | 0.32 | 1.0 |
Weight loss | 19 (26%) | 13 (26%) | 6 (26.1%) | 0.99 | 1.0 |
Raynaud’s | 18 (24.7%) | 12 (24%) | 6 (26.1%) | 0.85 | 1.0 |
Arthralgias | 16 (21.9%) | 10 (20%) | 6 (26.1%) | 0.56 | 1.0 |
Sicca symptoms | 13 (17.8%) | 9 (18%) | 4 (17.4%) | 1.0 | 1.0 |
Alopecia | 5 (6.8%) | 4 (8%) | 1 (4.4%) | 1.0 | 1.0 |
Scleroderma/dactyly | 7 (9.6%) | 6 (12%) | 1 (4.4%) | 0.42 | 1.0 |
Any rheum symptoms | 49 (67.1%) | 35 (70%) | 14 (60.9%) | 0.44 | 1.0 |
None | 24 (32.9%) | 15 (30%) | 9 (39.1%) | 0.44 | 1.0 |
Prior CTD diagnosis, n (%) | 0.97 | 1.0 | |||
RA | 1 (1.4%) | 1 (2%) | 0 (0%) | ||
Sjogren’s | 3 (4.1%) | 2 (4%) | 1 (4.4%) | ||
Scleroderma | 4 (5.5%) | 3 (6%) | 1 (4.4%) | ||
SLE | 3 (4.1%) | 2 (4%) | 1 (4.4%) | ||
DM/PM | 2 (2.7%) | 1 (2%) | 1 (3.7%) | ||
MCTD | 3 (4.1%) | 3 (6%) | 0 (0%) | ||
None | 57 (78%) | 38 (76%) | 19 (82.6%) | ||
Met diagnostic criteria for a CTD, n (%) | 0.02 | 0.48 | |||
Anti-synthetase | 5 (6.9%) | 0 (0%) | 5 (21.7%) | ||
DM/PM | 5 (6.9%) | 3 (6%) | 2 (8.7%) | ||
MCTD | 3 (4.1%) | 3 (6%) | 0 (0%) | ||
PMR | 1 (1.4%) | 1 (2%) | 0 (0%) | ||
SLE | 2 (2.7%) | 1 (2%) | 1 (4.4%) | ||
Scleroderma | 4 (5.5%) | 3 (6%) | 1 (4.4%) | ||
None | 53 (72.6%) | 39 (78%) | 14 (60.9%) | ||
Met IPAF criteria, n (%) | 36 (49.3%) | 27 (54%) | 9 (39.1%) | 0.24 | 1.0 |